OM:VITR

Stock Analysis Report

Executive Summary

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Vitrolife's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.7%

OM:VITR

-0.9%

SE Biotechs

0.2%

SE Market


1 Year Return

52.5%

OM:VITR

-18.8%

SE Biotechs

-1.9%

SE Market

VITR outperformed the Biotechs industry which returned -19.7% over the past year.

VITR outperformed the Market in Sweden which returned -2.6% over the past year.


Share holder returns

VITRIndustryMarket
7 Day-0.7%-0.9%0.2%
30 Day5.4%-7.4%-3.7%
90 Day-11.1%-2.2%-1.5%
1 Year53.1%52.5%-18.5%-18.8%2.2%-1.9%
3 Year87.4%84.6%42.7%31.7%26.0%7.4%
5 Year732.1%706.7%54.6%53.5%45.6%14.9%

Price Volatility Vs. Market

How volatile is Vitrolife's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vitrolife undervalued based on future cash flows and its price relative to the stock market?

57.99x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Vitrolife's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Vitrolife's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Vitrolife is overvalued based on earnings compared to the SE Biotechs industry average.

Vitrolife is overvalued based on earnings compared to the Sweden market.


Price Based on Expected Growth

Vitrolife is poor value based on expected growth next year.


Price Based on Value of Assets

Vitrolife is overvalued based on assets compared to the SE Biotechs industry average.


Next Steps

Future Growth

How is Vitrolife expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

14.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Vitrolife's revenue is expected to grow by 10.4% yearly, however this is not considered high growth (20% yearly).

Vitrolife's earnings are expected to grow by 14.1% yearly, however this is not considered high growth (20% yearly).

Vitrolife's revenue growth is expected to exceed the Sweden market average.

Vitrolife's earnings growth is expected to exceed the Sweden market average.

Vitrolife's earnings growth is expected to exceed the low risk savings rate of 0.4%.


Earnings per Share Growth Estimates


Future Return on Equity

Vitrolife is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Vitrolife performed over the past 5 years?

23.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Vitrolife has delivered over 20% year on year earnings growth in the past 5 years.

Vitrolife's 1-year earnings growth is less than its 5-year average (19.5% vs 23.6%)

Vitrolife's earnings growth has not exceeded the SE Biotechs industry average in the past year (19.5% vs 29.4%).


Return on Equity

Vitrolife has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Vitrolife used its assets more efficiently than the SE Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Vitrolife has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Vitrolife's financial position?


Financial Position Analysis

Vitrolife is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Vitrolife's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Vitrolife's level of debt (4.9%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (9% vs 4.9% today).

Debt is well covered by operating cash flow (424.4%, greater than 20% of total debt).

Vitrolife earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 11.6x debt.


Next Steps

Dividend

What is Vitrolife's current dividend yield, its reliability and sustainability?

0.71%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Vitrolife's pays a lower dividend yield than the bottom 25% of dividend payers in Sweden (1.97%).

Vitrolife's dividend is below the markets top 25% of dividend payers in Sweden (4.54%).

Vitrolife is not paying a notable dividend for Sweden, therefore no need to check if the payments are stable.

Vitrolife is not paying a notable dividend for Sweden, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Vitrolife's dividends as it is not paying a notable one for Sweden.


Future Payout to Shareholders

No need to calculate the sustainability of Vitrolife's dividends in 3 years as they are not expected to pay a notable one for Sweden.


Next Steps

Management

What is the CEO of Vitrolife's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Thomas Axelsson (60yo)

7.3yrs

Tenure

0

Mr. Thomas Axelsson, M.Sc. employed at Vitrolife AB (publ) in 2011 and has been its Chief Executive Officer of since April 18, 2012. Mr. Axelsson served as an Acting Chief Executive Officer of Vitrolife fr ...


CEO Compensation Analysis

Thomas's remuneration is lower than average for companies of similar size in Sweden.

Thomas's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.9yrs

Average Tenure

47yo

Average Age

The average tenure for the Vitrolife management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.6yrs

Average Tenure

60yo

Average Age

The average tenure for the Vitrolife board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Vitrolife individual insiders in the past 3 months.


Recent Insider Transactions

Buykr100,00027 May 19
Mikael Engblom
EntityIndividual
Role
Chief Financial Officer
CFO & Investor Relations
Shares500
Max Pricekr200.00
Buykr41,00024 May 19
Thomas Axelsson
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares200
Max Pricekr205.00
Sellkr2,005,00015 May 19
Mikael Engblom
EntityIndividual
Role
Chief Financial Officer
CFO & Investor Relations
Shares10,000
Max Pricekr201.00
Buykr100,16613 May 19
Mikael Engblom
EntityIndividual
Role
Chief Financial Officer
CFO & Investor Relations
Shares490
Max Pricekr204.42
Buykr73,53827 Nov 18
Mikael Engblom
EntityIndividual
Role
Chief Financial Officer
CFO & Investor Relations
Shares472
Max Pricekr155.80
Buykr82,99204 Oct 18
Thomas Axelsson
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares600
Max Pricekr138.32
Buykr117,74204 Oct 18
Barbro Fridén
EntityIndividual
Role
Member of the Board of Directors
Director
Shares850
Max Pricekr138.52
Buykr129,52703 Oct 18
Mikael Engblom
EntityIndividual
Role
Chief Financial Officer
CFO & Investor Relations
Shares952
Max Pricekr137.61

Ownership Breakdown


Management Team

  • Thomas Axelsson (60yo)

    Chief Executive Officer

    • Tenure: 7.3yrs
  • Fredrik Mattsson (47yo)

    Head of New Business & Strategic Development Function

    • Tenure: 0.9yrs
  • Martin Morén (47yo)

    Director of Human Resources

    • Tenure: 11.5yrs
  • Maria Forss (47yo)

    Business Unit Director of Media

    • Tenure: 1.9yrs
  • Mikael Engblom (42yo)

    CFO & Investor Relations

    • Tenure: 0.0yrs
  • Jan Nilsson

    Head Auditor

    • Tenure: 0.0yrs
  • Rickard Ericsson (48yo)

    Chief Sales & Marketing Officer

    • Tenure: 1.9yrs
  • Steffen Nielsen (42yo)

    Chief Operating Officer

    • Tenure: 1.9yrs
  • Mark Larman (45yo)

    Chief Scientific Officer

    • Tenure: 2.0yrs

Board Members

  • Henrik Blomquist (48yo)

    Director

    • Tenure: 0.3yrs
  • Jón Sigurdsson (63yo)

    Chairman

    • Tenure: 0.3yrs
  • Lars Holmqvist (60yo)

    Director

    • Tenure: 1.6yrs
  • Barbro Fridén (63yo)

    Director

    • Tenure: 9.3yrs
    • Compensation: kr110.00k
  • Pia Marions (56yo)

    Director

    • Tenure: 6.3yrs

Company Information

Vitrolife AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vitrolife AB (publ)
  • Ticker: VITR
  • Exchange: OM
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr19.659b
  • Shares outstanding: 108.55m
  • Website: https://www.vitrolife.com

Number of Employees


Location

  • Vitrolife AB (publ)
  • Gustaf Werners gata 2
  • Västra Frölunda
  • Gothenburg
  • 421 32
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VITROM (OMX Nordic Exchange Stockholm)YesCommon SharesSESEKJun 2001
VTFNDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2001
0YAYLSE (London Stock Exchange)YesCommon SharesGBSEKJun 2001
VTRL.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDMay 2016

Biography

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 20:47
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.